Leonardo Farol

Leonardo Farol, M.D.

  • Staff Physician, Department of Hematology & Hematopoietic Cell Transplantation

Leonardo Farol, M.D.

  • 2008-Present, Staff Physician, Kaiser Permanente/City of Hope, Department of Hematology & Hematopoietic Cell Transplantation
  • 2006-2008, Kaiser Permanente Fontana, Dept of Hematology/Oncology

Locations

Duarte

1500 East Duarte Road, Duarte, CA, 91010

Get Directions

Phone :  626-256-4673

Degrees

  • 1998, M.D., University of California, Irvine, CA
  • 1994, B.A., Biochemistry, Occidental College, Los Angeles, CA

Fellowship

  • 2005-2006, Bone Marrow Transplant Fellowship, City of Hope, Duarte, CA
  • 2002-2005, Hematology/Oncology, New York University, New York, NY

Residency

  • 1998-2001, Internal Medicine, Northwestern University (Evanston Northwestern Healthcare), Evanston, IL
  • 2002, American Board of Internal Medicine
  • 2005, Medical Oncology
  • 2005, Hematology
  • Farol L, Hymes K: Bexarotene: A Clinical Review. Expert Rev Anticancer Therapy (2004) 4(2): 180- 8. PMID: 15056048
  • Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2012 Mar;l8(3):486-92. doi: 10.1016/j.bbmt.2011.12.580. Epub 2011 Dec 22. PMID: 22198542
  • Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, Forman SJ, Gopal AK. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012 Jun 28;119(26):6379-81. DOI:10.1182/blood-2012-03-418673. Epub 2012 May 18. PMID: 22611160
  • Krishnan AY, Wang S, Palmer JM, Tsai NC, Thomas SH, Htut M, Farol L, Forman SJ. A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myeloma. Leuk Lymphoma. 2014 Jan;55(1):201-3. DOI: 10.3109/10428194.2013.794268. No abstract available. PMID:23573824
  • Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L, Farol L, Nademanee A, Forman SJ. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation/or Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014 Nov;20(11):1864-8. DOI: 10.1016/j.bbmt.2014.06.037. PMID:25008328
  • Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016 Apr 1;34(10):1122-30. DOI: 10.1200/JCO.2015.64.0409. PMID:26834065
  • Nakamura R, La Rosa C, Longmate J, Drake J, Slape C, Zhou Q, Lampa MG, O'Donnell M, Cai JL, Farol L, Salhotra A, Snyder DS, Aldoss I, Forman SJ, Miller JS, Zaia JA, Diamond DJ. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF035 l 2676 (CMVPep Vax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1 b trial. Lancet Haematol. 2016 Feb;3(2):e87-98. DOI: 10.1016/S2352-3026(15)00246-X. PMID:26853648
  • Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Khaled S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplant Conditioning in Patients with Relapsed/Refractory Acute Leukemia. Biol Blood Marrow Transplant. 2017 Jan 10. pii: S1083- 8791(17)30192-l. DOI: 10.1016/j.bbmt.2017.01.067. [Epub ahead of print]
Back To Top